Clinical Research Directory
Browse clinical research sites, groups, and studies.
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
Sponsor: Janssen Sciences Ireland UC
Summary
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source \[example, access program or government program\]), or local standard of care, as appropriate.
Official title: Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Subjects
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2009-12-09
Completion Date
2026-04-06
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Etravirine
Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
Locations (29)
Los Angeles, California, United States
Washington D.C., District of Columbia, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Buenos Aires, Argentina
Ciudad Autonoma de Buenos Aire, Argentina
Belo Horizonte, Brazil
Ribeirão Preto, Brazil
Rio de Janeiro, Brazil
Montreal, Quebec, Canada
Lyon, France
Paris, France
Panama City, Panama
Rio Piedras, Puerto Rico
Bucharest, Romania
Bloemfontein, South Africa
Boksburg, South Africa
Cape Town, South Africa
Dundee, South Africa
Durban, South Africa
George, South Africa
Johannesburg, South Africa
Newtown, South Africa
Pretoria, South Africa
Esplugues de Llobregat, Spain
Madrid, Spain
Seville, Spain
Bangkok, Thailand
Khon Kaen, Thailand